Doppl SA

🌟 The Importance of Alveolar Organoids in Lung Health and Disease Research 🌟   Doppl SA’s alveolar organoids exhibit expression of surfactant protein C (SPC), a critical marker of alveolar type II (AT2) cells.   🌬️ Why AT2 cells matter? AT2 cells are essential for lung health, homeostasis and injury response. They maintain the alveolar epithelium and produce surfactant and support lung repair by differentiating into alveolar type I (AT1) cells when needed. Dysfunction in AT2 cells is linked to serious conditions like idiopathic pulmonary fibrosis (IPF).   Our AT2-enriched alveolar organoids enable in-depth studies of lung disease mechanisms and serve as a valuable platform for testing therapies aimed at restoring AT2 function.   Curious to learn more? Reach out at info@doppl.ch!   Image credit: Camilla Ceroni  #DopplSA #organoids #lung_organoids #ModelDevelopment #innovation #partnership

Why study gut biology with small intestinal #organoids from multiple species? At Doppl SA, we harness organoids from humans, mice, rats, dogs, and monkeys to: 🔍 Unlock Cross-Species Insights: Understand the differences in gut biology and disease mechanisms across species, deepening our knowledge. 💊 Enhance Drug Development: Predict drug effects more accurately, paving the way for better treatments with fewer setbacks. 🔬 Drive Precision in Disease Research: Gain valuable insights into gut diseases like IBD and cancer by studying them across multiple species. Get in touch at info@doppl.ch to discover how our multi-species organoids can take your research to the next level! #DopplSA #organoids #3Dbiology #MultiSpecies #DrugDevelopment #innovation #partnership

📢 Publication Alert! We are excited to share that our review titled "iPSC-Derived and Patient-Derived Organoids: Applications and Challenges in Scalability and Reproducibility as Pre-Clinical Models” has just been published in Current Research in Toxicology (CRTox)! In this review, we explore the immense potential of organoids in pre-clinical research, highlighting the key challenges related to scalability and reproducibility. A huge thanks to our amazing team and our collaborators at CHUV | Lausanne university hospital for making this possible: Elisa Heinzelmann, PhD, Francesco Piraino, PhD, Mariana Costa, Aline Roch, Maxim Norkin, Virginie Garnier, Krisztian Homicsko and Nathalie Brandenberg! 🙌  Check out the full article here:👇https://lnkd.in/ey2CgkKT #DopplSA #CHUV #organoids #review #3Dbiology #innovation https://lnkd.in/e4bJC94B

Exciting news from Basel! BioTechX has officially kicked off! 🇨🇭 Make sure to stop by our booth S30 and visit our poster (#49) where we will be showcasing our innovative organoid solutions. See you there or reach out at info@doppl.ch #BioTechX #Basel #DopplSA #organoid #3Dbiology #innovation #networking

🔬Discover Doppl SA’s organoids derived from multiple species, including human, mouse, rat, dog and monkey! These 3D models provide valuable insights into species-specific differences, disease progression, and drug responses. By leveraging these organoids, we can enhance preclinical testing and reduce reliance on animal models, paving the way for more accurate and ethical drug development. You want to learn more? Reach out at info@doppl.ch #DopplSA #organoids #3Dbiology #innovation #partnership

Doppl SA is getting ready for Europe's largest pharmaceutical development  and healthcare event: The BioTechX EU 2024 in Basel! 🇨🇭 📍Find us at booth #S30 in the #startup zone and learn about our 3D #organoid solutions for drug development and personalized medicine! 📅 Don’t miss Juliane Dervaux presenting how "ML-Driven, Label-Free Image Analysis Enhances Functional Assays for Cystic Fibrosis in Patient-Derived Organoids" on Day 1 (Poster session; 10:40-11:40 AM) 💡 Are you attending too? Let’s connect or reach out to schedule a meeting at info@doppl.ch! #BioTechX #DopplSA #innovation #organoids #DrugDevelopment #PersonalizedMedicine

Last week, Doppl SA attended the Ilmac conference in #Lausanne🇨🇭, where I had the pleasure to give my first pitch for our company! 🎤 It was an exciting experience to share Doppl SA's vision and cutting-edge solutions, leveraging our innovative #organoid models for advanced drug development and safety studies. 💊 A huge thank you to everyone who attended, supported, and engaged with us at Ilmac. Looking forward to more amazing opportunities ahead! 💡 #ILMAC #Lausanne #DopplSA #innovation #organoids #drugdevelopment #partnership

Last week, we had a fantastic time at Ilmac in our beautiful hometown of #Lausanne!🇨🇭 A huge thank you to everyone who made this event a success. We loved the lively conversations and new connections. Special thanks to BioAlps - Swiss Health Valley for hosting us at their booth! Looking forward to continuing these discussions and driving innovation together! Missed us at the event? Feel free to reach out at info@doppl.ch. #ILMAC #Lausanne #DopplSA #innovation #organoids #partnership

Doppl SA is taking part in Ilmac 2024 in Lausanne! Don’t miss the opportunity to meet us at the BioAlps - Swiss Health Valley booth (B101, Hall 36) and discover the fascinating world of organoid research. 🔬 Learn how our industry-standard organoids are transforming drug development, safety testing, and personalized medicine. See you there or reach out to schedule a meeting at info@doppl.ch #ILMAC2024 #DopplSA #partnership #organoids #DrugDevelopment #PersonalizedMedicine

Bi-specific antibodies are redefining the future of #immunotherapy 🎯 At Doppl SA, we have established a novel co-culture approach using healthy #organoids and colorectal tumoroids to better study the interaction between immune cells, healthy tissue, and cancer cells when exposed to T cell bi-specific antibodies. This method enables us to tackle the challenges of developing therapies with bi-specific antibodies, pushing the boundaries of precision immunotherapy. Want to learn more about our readouts to assess the #potency and #safety of bi-specific antibodies? Let’s connect at info@doppl.ch! #DopplSA #organoids #3Dbiology #immunotherapy #CancerResearch #innovation